HB Fuller Company formulates, manufactures and markets adhesives, sealants, coatings, polymers, tapes, encapsulants, additives and other specialty chemicals worldwide. The company is headquartered in Saint Paul, Minnesota.
| Revenue (TTM) | $3.51B |
| Gross Profit (TTM) | $1.14B |
| EBITDA | $605.88M |
| Operating Margin | 13.30% |
| Return on Equity | 9.39% |
| Return on Assets | 5.05% |
| Revenue/Share (TTM) | $64.33 |
| Book Value | $38.72 |
| Price-to-Book | 1.51 |
| Price-to-Sales (TTM) | 0.87 |
| EV/Revenue | 1.454 |
| EV/EBITDA | 9.13 |
| Quarterly Earnings Growth (YoY) | 61.80% |
| Quarterly Revenue Growth (YoY) | 5.80% |
| Shares Outstanding | $53.79M |
| Float | $53.47M |
| % Insiders | 0.29% |
| % Institutions | 109.72% |
Volatility is currently contracting
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
FUL is tapping medical, aerospace and pricing trends to support margins, but volume weakness still clouds its path to stronger growth.
FUL trades near the low end of its five-year valuation range as improving earnings meet volume, inflation and leverage risks tied to its medical-market expansion.
FUL's outlook rests on pricing, margins and portfolio reshaping as medical expansion and M&A aim to offset uneven demand across key end markets.
Investors interested in stocks from the Chemical - Specialty sector have probably already heard of H. B. Fuller (FUL) and PPG Industries (PPG).
FUL flags stronger pricing, higher profit guidance and a proposed AMS deal aimed at expanding its medical adhesives platform and boosting margins.
H.B. Fuller is rated a "buy" with a conservative $80/share price target, reflecting improved fundamentals and recent M&A. FUL's recent results validate earnings recovery: near-6% revenue growth, ~20% AEPS improvement, double-digit EBITDA gains, and record operating cash flow. The AMS acquisition is expected to drive margin expansion, higher-quality revenue, and meaningful revenue and cost synergies, supporting long-term profitability.
H.B. Fuller Company (FUL) Q2 2026 Earnings Call Transcript
CLEVELAND--(BUSINESS WIRE)--Ancora Holdings Group, LLC (collectively with its affiliates, “Ancora” or “we”) today released the below statement regarding H.B. Fuller Company (NYSE: FUL) (“H.B. Fuller” or the “Company”) and Advanced Medical Solutions Group plc (“AMS”). Previously, Ancora issued a letter to H.B. Fuller's Board of Directors (the “Board”) regarding its contemplated acquisition of AMS. Fredrick D. DiSanto, Chairman and Chief Executive Officer of Ancora, and James Chadwick, President.
Shares in Advanced Medical Solutions Group (AIM:AMS) rose 16% to 278.14p after the company agreed to a recommended cash takeover by H.B. Fuller, the US adhesives group, valuing it at about £659 million.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on FUL and any ticker you trade — then tracks every position and per-strategy win rate.
